双倍剂量坦索罗辛对良性前列腺增生引起的下尿路症状的临床研究被引量：6

Clinical study of double dose of Tamsulosin for lower urinary tract symptoms caused by benign prostatic hyperplasia

下载PDF

导出

摘要目的：探讨双倍剂量坦索罗辛对良性前列腺增生引起的下尿路症状的疗效。方法将2010年6月～2012年6月河南省驻马店市中心医院确诊的64例良性前列腺增生（BPH）伴下尿路症状（LUTS）患者按1：1的比例完全随机分配到双倍剂量组（坦索罗辛0.4 mg）和推荐剂量组（坦索罗辛0.2 mg）各32例，进入8周的双盲药物治疗期。比较两组治疗8周后临床症状的疗效以及两组治疗前后国际前列腺症状评分（IPSS）、生命质量评分（QOL）、储尿期症状评分（SSS）、最大尿流率（Qmax）、残余尿量（RV）及前列腺体积的变化情况。结果双倍剂量组的临床症状改善率明显高于推荐剂量组（87.5%比68.8%）（P〈0.05）。治疗后两组IPSS、QOL、SSS、Qmax、RV均较各组治疗前有显著变化（P〈0.01或P〈0.05），但治疗后两组组间比较差异无统计学意义（P〉0.05），其中双倍剂量组Qmax治疗后较推荐剂量组明显提高[（13.75±2.47）mL/s比（10.21±1.65）mL/s]（P〈0.05）。两组前列腺体积治疗前后组内及组间比较差异均无统计学意义（P〉0.05）。结论双倍剂量坦索罗辛对BPH患者自觉症状和Qmax较推荐剂量有明显的改善作用，但仍需要大规模的前瞻性的随机对照试验来进一步证实双倍剂量坦索罗辛长期用药的安全性、有效性。 Objective To investigate the efficacy of double dose of Tamsulosin in the treatment of lower urinary tract symptoms （LUTS） caused by benign prostatic hyperplasia （BPH）. Methods 64 patients associated with BPH caused by LUTS from June 2010 to June 2012 in Zhumadian Central Hospital were randomly divided into double-dose group （Tamsulosin 0.4 mg） and recommended dose group （Tamsulosin 0.2 mg） accoding to 1：1 ratio, with 32 cases in each group, entered 8 weeks of double-blind drug treatment. The efficacy and the clinical symptoms, international prostate symptom score （IPSS）, quality of life （QOL）, storage symptom scores （SSS）, maximum flow rate （Qmax）, residual volume （RV） and prostate volume changes were compared between the two groups after treatment for 8 weeks. Results The im-provement rate of clinical symptoms of the double-dose group was significantly higher than the recommended dose group, the difference was significant （87.5% v s 68.8%, P〈 0.05）. After treatment, IPSS, QOL, SSS, Qmax, RV of two groups significantly changed than before treatment （P〈 0.01 or P〈 0.05）, but there was no significant difference be-tween two groups. Qmax of double-dose group improved significantly than the recommended dose group, the difference was significant [（13.75±2.47） mL/s v s （10.21±1.65） mL/s] （P〈 0.05）. There was no significant difference of prostate volume within the group and between two groups before treatment and after treatment （P〉0.05）. Conclusion Double dose of Tamsulosin can significantly improve subjective symptoms and Qmax of patients with BPH compared with the recommended dose, but it still needs large prospective randomized controlled trials to prove the safety and effectiveness of double dose of Tamsulosin for a long-term medication.

作者徐海亮

机构地区河南省驻马店市中心医院泌尿外科

出处《中国医药导报》 CAS 2015年第18期122-125,共4页 China Medical Herald

关键词良性前列腺增生下尿路症状坦索罗辛双倍剂量 Benign prostatic hyperplasia Lower urinary tract symptoms Tamsulosin Double dose

分类号 R697.32 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献15

1Kaplan SA. Re:long-term treatment and prognostic factors of alphal-blockers for lower urinary tract symptoms asso- ciated with benign prostatic hyperplasia:a pilot study comparing naftopidil and tamsulosin hydrochloride [J]. J Urol,2011,185(1) :227.
2Kojima Y,Sasaki S, Imura M,et al. Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria:a prospective open-label long-term study using frequency-volume chart [J]. Neu- rourol Urodyn, 2012,31 ( 1 ) : 80-85.
3Chapple CR. Pharmacotherapy for benign prostatic hyper- plasia-the potential for alpha 1-adrenoceptor subtype- specific blockade [J]. Br J Urol, 1998,81 (Suppl 1 ) : 34-47.
4Chung MS, Lee SH, Park KK, et al. Comparative rapid on- set of efficacy between doxazosin gastrointestinal thera- peutic system and tamsulosin in patients with lower uri- nary tract symptoms from benign prostatic hyperplasia:a muhicentre,prospective,randomized study [J]. Int J Clin Pract,2011,65(11) : 1193-1199.
5Gacci M, Vittori G,Tosi N, et al. A randomized, placebo- controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia [J]. J Sex Med,2012,9(6) : 1624-1653.
6Perincbery N. Ing-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associ- ated with benign prostatic hyperplasia [J]. J Urol,2003, 170(2 Pt 1) :498-502.
7Mohammadi -Fallah M, Hamedanchi S, Tayyebi -Azar A. Preventive effect of tamsulosin on postoperative urinary re- tention [J]. Korean J Urol,2012,53(6):419-423.
8Djavan B,Dianat SS,Kazzazi A. Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia:clinical utility of dutasteride and tamsulosin [J]. Patient Relat Outcome Meas,2011,2:71-79.
9Chapple CR,Wyndaele JJ,Nordling J,et al. Tamsulosin,the first prostate-selective alpha 1A-adrenoceptor antag- onist. A meta-analysis of two randomized, placebo-con- trolled, multicentre studies in patients with benign pro- static obstruction (symptomatic BPH). European Tamsu- losin Study Group [J]. Eur Urol, 1996,29(2) : 155-167.
10李青,李明川,姜永光,刘俊敏.大剂量坦索罗辛治疗良性前列腺增生引起下尿路症状的前瞻性研究[J].中华泌尿外科杂志,2012,33(2):117-119. 被引量：13

二级参考文献21

1王东文,双卫兵.膀胱过度活动症[J].临床泌尿外科杂志,2005,20(7):445-447. 被引量：8
2Martin JO, Afrcsi CM. Effects of transurethral resection of prostate on the quality of life of hyper patients with benign prostatec hyperplasia. J Am Coll Surg, 2004,198 (3) : 394-403.
3Roehrborn CG, McConnell JD. Etiology, pat.hophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughn ED, et al, editors. Campbell' s Urology. 8th ed. Philadelphia: WB Saunders Co, 2002: 1297- 1330.
4Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men : focus on the bladder. Eur Urol, 2006,49 (4) 651-659.
5Chancellor M, Freeman S, Mitcheson HD, et al. Tolterodine, an effective and well tolterated treatment for urge incontinence and other overactive bladder symtoms. Clin Drug Invest,2000, 19(2) : 83-91.
6Irwin DE, Milsom I,Hunskaar S,et al.Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study[J]. Eur Urol,2006,50:1306-1315.
7Abdel-Aziz KF,Lemack GE. Overactive bladder Jn the male patient:bladder, outlet, or both? [J]. Curr Urol Rep,2002,3:445-451.
8Park CH, Chang HS, Oh BR,et al. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia:a nonblind multicentre korean study[J]. Clin Drug Investig, 2004,24:41--47.
9Kojima Y, Sasaki S, Imura M, et al. Tamsulosin reduces night- time urine production in benign prostatic hyperplasia patients with nocturnal polyuria: a prospective open-label long-term study using frequency-volume chart [ J/OL]. Neurourol Urodyn, 2011 [ 2012-01-15 ]. http://onlinelibrary, wiley, com/doi/10. 1002/ nau. 21224/abstract. [ published online ahead of printl.
10Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analy. sis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic ob- struction (symptomatic BPH). Eur Urol, 1996, 29 : 145-154.